Skip to content

MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study)

Expression of Mitochondria-Endoplasmic Reticulum Contact Proteins in Saliva and Gingival Crevicular Fluid in Patients With Periodontal Disease: ELISA and Calcium Analysis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07601685
Acronym
EKNMERC-GCF-SL
Enrollment
48
Registered
2026-05-22
Start date
2024-01-10
Completion date
2025-04-01
Last updated
2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biomarker Discovery and Validation, Gingivitis and Periodontal Diseases, Pathways, Periodontitis

Keywords

MERC, Mitochondria-Endoplasmic Reticulum Contact, VAPB, PTPIP51, IP3R, GRP75, VDAC, Caspase-3, Reactive Oxygen Species, Calcium, Gingival Crevicular Fluid, Saliva, ELISA, Oxidative Stress, Apoptosis

Brief summary

This observational cross-sectional study investigates the levels of mitochondria-endoplasmic reticulum contact site (MERC) proteins in saliva and gingival crevicular fluid (GCF) of individuals with different periodontal conditions. MERCs are specialized regions where mitochondria and the endoplasmic reticulum physically connect, and they play important roles in calcium signaling, oxidative stress regulation, and cell death (apoptosis). Disruption of these contact sites has been linked to inflammatory diseases, including periodontal disease. The study includes 48 systemically healthy, non-smoking adults divided into three groups: periodontally healthy (n=16), gingivitis (n=16), and Stage III Grade B periodontitis (n=16). Five MERC-associated proteins (VAPB, PTPIP51, IP3R, GRP75, and VDAC) are measured in GCF and saliva samples using ELISA. Additionally, caspase-3 (a marker of apoptosis), reactive oxygen species (a marker of oxidative stress), and calcium levels are measured to explore relationships between MERC proteins and key cellular processes involved in periodontal tissue destruction. The purpose of this study is to determine whether MERC protein levels differ across periodontal conditions and to evaluate their associations with clinical periodontal parameters, oxidative stress, calcium metabolism, and apoptosis.

Detailed description

Mitochondria-endoplasmic reticulum contact sites (MERCs) are specialized structural domains that physically link mitochondria and the endoplasmic reticulum. These contact sites are enriched with functional proteins that coordinate calcium transfer between the two organelles, regulate lipid metabolism, modulate oxidative stress responses, and control apoptotic signaling pathways. Key MERC-associated proteins include VAPB (vesicle-associated membrane protein-associated protein B), PTPIP51 (protein tyrosine phosphatase-interacting protein 51), IP3R (inositol 1,4,5-trisphosphate receptor), GRP75 (glucose-regulated protein 75), and VDAC (voltage-dependent anion channel). The IP3R-GRP75-VDAC complex facilitates calcium transfer from the ER to mitochondria, while the VAPB-PTPIP51 complex modulates this process and influences ATP production and autophagy. Disruption of MERC homeostasis has been implicated in neurodegenerative diseases, metabolic disorders, and periodontal disease. Periodontal disease is a chronic inflammatory condition driven by microbial dental plaque, leading to destruction of periodontal tissues and alveolar bone. Previous studies demonstrated dysregulation of MERC-related gene expression (MFN1, IP3R, GRP75, PINK1, SIGMAR1) in human gingival fibroblasts exposed to Porphyromonas gingivalis and Fusobacterium nucleatum. The present study measures the concentrations and total amounts of five MERC proteins-VAPB, PTPIP51, IP3R, GRP75, and VDAC-together with caspase-3 (an apoptosis marker), reactive oxygen species (ROS, an oxidative stress marker), and calcium levels in gingival crevicular fluid (GCF) and unstimulated whole saliva obtained from systemically healthy, non-smoking participants. Participants are classified into three groups according to the 2017 World Workshop classification: periodontally healthy (n=16), gingivitis (n=16), and Stage III Grade B periodontitis (n=16), with equal sex distribution (8 males and 8 females per group). GCF samples are collected from three single-rooted teeth per participant using standardized paper strips (Periopaper), with absorbed volume measured using a Periotron 8000. Saliva samples are collected using the passive drooling method. Biomarker levels are quantified using commercially available ELISA kits. Clinical periodontal parameters recorded include Plaque Index (PI), Gingival Index (GI), Probing Depth (PD), Bleeding on Probing (BOP%), and Clinical Attachment Level (CAL). Correlations between biomarker levels and clinical parameters are analyzed. Receiver operating characteristic (ROC) curve analysis is performed to evaluate the diagnostic potential of the biomarkers.

Interventions

Levels of MERC-associated proteins (VAPB, PTPIP51, IP3R, GRP75, VDAC), caspase-3, reactive oxygen species, and calcium were measured in gingival crevicular fluid and unstimulated whole saliva samples using commercially available ELISA kits. Absorbance was read at 450 nm. No therapeutic intervention was applied; this is an observational biomarker measurement study.

DIAGNOSTIC_TESTCalcium Measurement

Calcium levels were measured in gingival crevicular fluid and unstimulated whole saliva samples using a commercially available ELISA kit (ELK Biotechnology, China). Concentrations were expressed as μmol/mL and total amounts as μmol/30s. Analytical range: 0.15-40 μmol/mL. No therapeutic intervention was applied.

Sponsors

Inonu University
Lead SponsorOTHER
Harvard University
CollaboratorOTHER
University of Minnesota
CollaboratorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Systemically healthy individuals aged 18-65 years * Non-smokers or smoking cessation more than 5 years ago * Healthy group: No history of periodontal disease, ≥20 teeth, probing depth (PD) ≤3 mm at all sites, bleeding on probing (BOP) \<10%, radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth * Gingivitis group: No history of periodontal disease, ≥20 teeth, PD ≤3 mm at all sites, BOP ≥30%, radiographic CEJ-to-alveolar bone crest distance ≤3 mm in ≥95% of teeth * Periodontitis group: ≥15 teeth, \>30% of teeth affected by periodontal disease, PD ≥6 mm, clinical attachment loss (CAL) ≥5 mm, vertical bone loss ≥3 mm, Class II or III furcation involvement, radiographic alveolar bone loss extending to the middle third or beyond (≥33%), bone loss-to-age ratio between 0.25 and 1.00

Exclusion criteria

* Periodontal treatment or antibiotic use within the past 6 months * Fewer than 20 teeth (excluding third molars) * Presence of any systemic disease * Current smoking or cessation within the past 5 years * Use of immunosuppressive medication * Alcohol consumption * Regular medication use * Pregnancy or lactation * Need for antibiotic prophylaxis prior to dental procedures * Prosthetic restorations on the teeth selected for sampling

Design outcomes

Primary

MeasureTime frameDescription
GCF VAPB LevelsAt baseline (single visit)Concentrations and total amounts of VAPB in gingival crevicular fluid measured by ELISA.
Salivary VAPB LevelsAt baseline (single visit)Concentrations of VAPB (pg/mL) in unstimulated whole saliva measured by ELISA.
GCF PTPIP51 LevelsAt baseline (single visit)Concentrations and total amounts of PTPIP51 in gingival crevicular fluid measured by ELISA.
Salivary PTPIP51 LevelsAt baseline (single visit)Concentrations of PTPIP51 (ng/L) in unstimulated whole saliva measured by ELISA.
GCF IP3R LevelsAt baseline (single visit)Concentrations and total amounts of IP3R in gingival crevicular fluid measured by ELISA.
Salivary IP3R LevelsAt baseline (single visit)Concentrations of IP3R (ng/mL) in unstimulated whole saliva measured by ELISA.
GCF GRP75 LevelsAt baseline (single visit)Concentrations and total amounts of GRP75 in gingival crevicular fluid measured by ELISA.
Salivary GRP75 LevelsAt baseline (single visit)Concentrations of GRP75 (ng/mL) in unstimulated whole saliva measured by ELISA.
GCF VDAC LevelsAt baseline (single visit)Concentrations and total amounts of VDAC in gingival crevicular fluid measured by ELISA.
Salivary VDAC LevelsAt baseline (single visit)Concentrations of VDAC (ng/mL) in unstimulated whole saliva measured by ELISA.
GCF Caspase-3 LevelsAt baseline (single visit)Concentrations and total amounts of caspase-3 (ng/mL) in gingival crevicular fluid measured by ELISA.
Salivary Caspase-3 LevelsAt baseline (single visit)Concentrations of caspase-3 (ng/mL) in unstimulated whole saliva measured by ELISA.
GCF Reactive Oxygen Species LevelsAt baseline (single visit)Concentrations and total amounts of reactive oxygen species (ROS) in gingival crevicular fluid measured by ELISA.
Salivary Reactive Oxygen Species LevelsAt baseline (single visit)Concentrations of reactive oxygen species (ROS) in unstimulated whole saliva measured by ELISA.
GCF Calcium LevelsAt baseline (single visit)Concentrations and total amounts of calcium (µmol/mL) in gingival crevicular fluid measured by ELISA.
Salivary Calcium LevelsAt baseline (single visit)Concentrations of calcium (µmol/mL) in unstimulated whole saliva measured by ELISA.
Plaque IndexAt baseline (single visit)Plaque Index (PI) recorded at sampling sites.
Gingival IndexAt baseline (single visit)Gingival Index (GI) recorded at sampling sites.
Probing DepthAt baseline (single visit)Probing Depth (PD) recorded at sampling sites.
Bleeding on ProbingAt baseline (single visit)Bleeding on Probing (BOP%) recorded at sampling sites.
Clinical Attachment LevelAt baseline (single visit)Clinical Attachment Level (CAL) recorded at sampling sites.
Gingival Crevicular Fluid VolumeAt baseline (single visit)Gingival crevicular fluid (GCF) volume measured at sampling sites.

Countries

Turkey (Türkiye)

Contacts

STUDY_CHAIRCüneyt A Aral, Professor, DDS, PhD

Inonu University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 23, 2026